查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2132243

體內細胞療法市場規模、佔有率和趨勢分析報告：按治療細胞類型、治療應用、體內細胞工程、給藥方法、地區和細分市場預測（2026-2033 年）

In Vivo Cell Therapy Market Size, Share & Trends Analysis Report By Therapeutic Cell Type, By Therapeutic Application, By In Vivo Cell-Engineering, By Delivery Modality, By Region, And Segment Forecasts, 2026 - 2033
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

體內細胞治療市場概覽

全球體內細胞治療市場預計到 2025 年將達到 2.292 億美元，到 2026 年將成長到 3.407 億美元，到 2033 年將達到 57.263 億美元，2026 年至 2033 年的複合年成長率為 49.6%。

北美引領全球市場，預計到 2025 年將佔據 55.9% 的最大銷售佔有率。這主要得益於對體內細胞療法開發的投資、靶向遞送技術的進步以及可程式設計細胞工程方法在精準醫療領域日益普及。

目錄

第1章：調查方法和範圍

第2章執行摘要

第3章 市場：變數、趨勢與範圍

  • 市場譜系展望
  • 市場動態
  • 產業分析工具

第4章：依治療性細胞類型進行業務分析

  • 體內細胞療法市場：按治療細胞類型分類的趨勢分析
  • 其他免疫細胞

第5章：依治療應用進行業務分析

  • 體內細胞療法市場：依治療應用分類的趨勢分析
  • 骨髓惡性腫瘤
  • 固體癌
  • 自體免疫疾病
  • 感染疾病
  • 其他

第6章：體內細胞工程的商業分析

  • 體內細胞療法市場：按體內細胞技術領域分類的趨勢分析
  • 受體工程
  • 基因編輯與基因改造
  • 瞬時基因編程
  • 其他細胞工程方法

第7章：以交付方式進行業務分析

  • 體內細胞療法市場：按給藥途徑分類的趨勢分析
  • 基於病毒載體的
  • 基於脂質奈米顆粒的
  • 其他非病毒遞送系統

第8章：區域商業分析

  • 體內細胞療法市場佔有率：按地區分類，2025 年和 2033 年
  • 北美洲
    • 2021-2033年北美體內細胞治療市場
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 2021-2033年歐洲體內細胞治療市場
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 2021-2033年亞太地區體內細胞治療市場
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 泰國
    • 韓國
  • 拉丁美洲
    • 2021-2033年拉丁美洲體內細胞療法市場
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 2021-2033年中東及非洲體內細胞治療市場
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第9章 競爭情勢

  • 公司分類
  • 企業市場占有率及定位分析，2025年
  • 策略規劃
  • 公司簡介列表
    • Gilead Sciences, Inc.
    • Legend BIoTech
    • Eli Lilly and Company
    • CRISPR Therapeutics
    • AbbVie Inc.
    • Umoja Biopharma
    • Ensoma, Inc.
    • Intellia Therapeutics, Inc.
    • Tessera Therapeutics
    • AstraZeneca
    • Johnson & Johnson
    • Valerio Therapeutics
Product Code: GVR-4-68041-007-7

In Vivo Cell Therapy Market Summary

The global in vivo cell therapy market size was valued at USD 229.2 million in 2025 and is projected to grow from USD 340.7 million in 2026 to USD 5726.3 million by 2033, at a CAGR of 49.6% from 2026 to 2033. North America dominated the global market, accounting for the largest revenue share of 55.9% in 2025. The investment in vivo cell therapy development, advances in targeted delivery technologies, and growing adoption of programmable cell-engineering approaches for precision medicine.

Global In Vivo Cell Therapy Market Report Segmentation

This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2021 to 2033. For the purpose of this report, Grand View Research has segmented the global in vivo cell therapy industry on the basis of therapeutic cell type, therapeutic application, in vivo cell-engineering, delivery modality, and region

  • Therapeutic Cell Type Outlook (Revenue, USD Million, 2021 - 2033)
  • T Cells
  • NK Cells
  • Myeloid Cells
  • Other Immune Cells
  • Therapeutic Application Outlook (Revenue, USD Million, 2021 - 2033)
  • Hematological Malignancies
  • Solid Tumors
  • Autoimmune Disease
  • Infectious Disease
  • Other Therapeutic Applications
  • In Vivo Cell- Engineering Outlook (Revenue, USD Million, 2021 - 2033)
  • Receptor Engineering
  • Gene Editing & Gene Modification
  • Transient Genetic Programming
  • Other Cell -Engineering Approaches
  • Delivery Modality Outlook (Revenue, USD Million, 2021 - 2033)
  • Viral Vector-based
  • Lipid Nanoparticle-based
  • Other Non-viral Delivery System
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • Thailand
    • South Korea
  • Latin America
    • Brazil
    • Argentina
  • Middle East and Africa (MEA)
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
    • 1.1.1. Segment Definitions
      • 1.1.1.1. Therapeutic Cell Type
      • 1.1.1.2. Therapeutic Application
      • 1.1.1.3. In Vivo Cell-Engineering
      • 1.1.1.4. Delivery Modality
  • 1.2. Regional Scope
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Objectives
  • 1.5. Research Methodology
  • 1.6. Information Procurement
    • 1.6.1. Purchased Database
    • 1.6.2. GVR's Internal Database
    • 1.6.3. Secondary Sources
    • 1.6.4. Primary Research
  • 1.7. Information or Data Analysis:
    • 1.7.1. Data Analysis Models
  • 1.8. Market Formulation & Validation
  • 1.9. Model Details
    • 1.9.1. Commodity Flow Analysis
    • 1.9.2. List of Secondary Sources
    • 1.9.3. List of Abbreviations

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Increasing Investment in In Vivo Cell Therapy Development
      • 3.2.1.2. Advances in Targeted Delivery Technologies
      • 3.2.1.3. Expansion of Programmable Cell Therapies for Precision Medicine
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Challenges in Achieving Precise and Targeted Delivery
      • 3.2.2.2. Regulatory Uncertainty for In Vivo Cell Therapies
    • 3.2.3. Market Opportunities Analysis
    • 3.2.4. Market Challenges Analysis
  • 3.3. Industry Analysis Tools
    • 3.3.1. Porter's Five Forces Analysis
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTLE Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Social landscape
      • 3.3.2.4. Economic landscape
      • 3.3.2.5. Legal landscape

Chapter 4. Therapeutic Cell Type Business Analysis

  • 4.1. Segment Dashboard
  • 4.2. In Vivo Cell Therapy Market: Therapeutic Cell Type Movement Analysis
    • 4.2.1. T Cells
    • 4.2.2. T Cells Market, 2021 - 2033 (USD Million)
    • 4.2.3. NK Cells
    • 4.2.4. NK Cells Kits Market, 2021 - 2033 (USD Million)
    • 4.2.5. Myeloid Cells
    • 4.2.6. Myeloid Cells Market, 2021 - 2033 (USD Million)
  • 4.3. Other Immune Cells
    • 4.3.1. Other Immune Cells Market, 2021 - 2033 (USD Million)

Chapter 5. Therapeutic Application Business Analysis

  • 5.1. Segment Dashboard
  • 5.2. In Vivo Cell Therapy Market: Therapeutic Application Movement Analysis
  • 5.3. Hematological Malignancies
    • 5.3.1. Hematological Malignancies Market, 2021 - 2033 (USD Million)
  • 5.4. Solid Tumors
    • 5.4.1. Solid Tumors Market, 2021 - 2033 (USD Million)
  • 5.5. Autoimmune Diseases
    • 5.5.1. Autoimmune Diseases Market, 2021 - 2033 (USD Million)
  • 5.6. Infectious Diseases
    • 5.6.1. Infectious Diseases Market, 2021 - 2033 (USD Million)
  • 5.7. Other Therapeutic Applications
    • 5.7.1. Other Therapeutic Applications Market, 2021 - 2033 (USD Million)

Chapter 6. In Vivo Cell-Engineering Business Analysis

  • 6.1. Segment Dashboard
  • 6.2. In Vivo Cell Therapy Market: In Vivo Cell-Engineering Movement Analysis
  • 6.3. Receptor Engineering
    • 6.3.1. Receptor Engineering Market, 2021 - 2033 (USD Million)
  • 6.4. Gene Editing & Gene Modification
    • 6.4.1. Gene Editing & Gene Modification Market, 2021 - 2033 (USD Million)
  • 6.5. Transient Genetic Programming
    • 6.5.1. Transient Genetic Programming Market, 2021 - 2033 (USD Million)
  • 6.6. Other Cell-Engineering Approaches
    • 6.6.1. Other Cell-Engineering Approaches Market, 2021 - 2033 (USD Million)

Chapter 7. Delivery Modality Business Analysis

  • 7.1. Segment Dashboard
  • 7.2. In Vivo Cell Therapy Market: Delivery Modality Movement Analysis
  • 7.3. Viral Vector-based
    • 7.3.1. Viral Vector-based Market, 2021 - 2033 (USD Million)
  • 7.4. Lipid Nanoparticle-based
    • 7.4.1. Lipid Nanoparticle-based Market, 2021 - 2033 (USD Million)
  • 7.5. Other Non-viral Delivery Systems
    • 7.5.1. Other Non-viral Delivery Systems Market, 2021 - 2033 (USD Million)

Chapter 8. Regional Business Analysis

  • 8.1. In Vivo Cell Therapy Market Share By Region, 2025 & 2033
  • 8.2. North America
    • 8.2.1. North America In Vivo Cell Therapy Market, 2021 - 2033 (USD Million)
    • 8.2.2. U.S.
      • 8.2.2.1. Key Country Dynamics
      • 8.2.2.2. Competitive Scenario
      • 8.2.2.3. Regulatory Framework
      • 8.2.2.4. U.S. In Vivo Cell Therapy Market, 2021 - 2033 (USD Million)
    • 8.2.3. Canada
      • 8.2.3.1. Key Country Dynamics
      • 8.2.3.2. Competitive Scenario
      • 8.2.3.3. Regulatory Framework
      • 8.2.3.4. Canada In Vivo Cell Therapy Market, 2021 - 2033 (USD Million)
    • 8.2.4. Mexico
      • 8.2.4.1. Key Country Dynamics
      • 8.2.4.2. Competitive Scenario
      • 8.2.4.3. Regulatory Framework
      • 8.2.4.4. Mexico In Vivo Cell Therapy Market, 2021 - 2033 (USD Million)
  • 8.3. Europe
    • 8.3.1. Europe In Vivo Cell Therapy Market, 2021 - 2033 (USD Million)
    • 8.3.2. UK
      • 8.3.2.1. Key Country Dynamics
      • 8.3.2.2. Competitive Scenario
      • 8.3.2.3. Regulatory Framework
      • 8.3.2.4. UK In Vivo Cell Therapy Market, 2021 - 2033 (USD Million)
    • 8.3.3. Germany
      • 8.3.3.1. Key Country Dynamics
      • 8.3.3.2. Competitive Scenario
      • 8.3.3.3. Regulatory Framework
      • 8.3.3.4. Germany In Vivo Cell Therapy Market, 2021 - 2033 (USD Million)
    • 8.3.4. France
      • 8.3.4.1. Key Country Dynamics
      • 8.3.4.2. Competitive Scenario
      • 8.3.4.3. Regulatory Framework
      • 8.3.4.4. France In Vivo Cell Therapy Market, 2021 - 2033 (USD Million)
    • 8.3.5. Italy
      • 8.3.5.1. Key Country Dynamics
      • 8.3.5.2. Competitive Scenario
      • 8.3.5.3. Regulatory Framework
      • 8.3.5.4. Italy In Vivo Cell Therapy Market, 2021 - 2033 (USD Million)
    • 8.3.6. Spain
      • 8.3.6.1. Key Country Dynamics
      • 8.3.6.2. Competitive Scenario
      • 8.3.6.3. Regulatory Framework
      • 8.3.6.4. Spain In Vivo Cell Therapy Market, 2021 - 2033 (USD Million)
    • 8.3.7. Denmark
      • 8.3.7.1. Key Country Dynamics
      • 8.3.7.2. Competitive Scenario
      • 8.3.7.3. Regulatory Framework
      • 8.3.7.4. Denmark In Vivo Cell Therapy Market, 2021 - 2033 (USD Million)
    • 8.3.8. Sweden
      • 8.3.8.1. Key Country Dynamics
      • 8.3.8.2. Competitive Scenario
      • 8.3.8.3. Regulatory Framework
      • 8.3.8.4. Sweden In Vivo Cell Therapy Market, 2021 - 2033 (USD Million)
    • 8.3.9. Norway
      • 8.3.9.1. Key Country Dynamics
      • 8.3.9.2. Competitive Scenario
      • 8.3.9.3. Regulatory Framework
      • 8.3.9.4. Norway In Vivo Cell Therapy Market, 2021 - 2033 (USD Million)
  • 8.4. Asia Pacific
    • 8.4.1. Asia Pacific In Vivo Cell Therapy Market, 2021 - 2033 (USD Million)
    • 8.4.2. Japan
      • 8.4.2.1. Key Country Dynamics
      • 8.4.2.2. Competitive Scenario
      • 8.4.2.3. Regulatory Framework
      • 8.4.2.4. Japan In Vivo Cell Therapy Market, 2021 - 2033 (USD Million)
    • 8.4.3. China
      • 8.4.3.1. Key Country Dynamics
      • 8.4.3.2. Competitive Scenario
      • 8.4.3.3. Regulatory Framework
      • 8.4.3.4. China In Vivo Cell Therapy Market, 2021 - 2033 (USD Million)
    • 8.4.4. India
      • 8.4.4.1. Key Country Dynamics
      • 8.4.4.2. Competitive Scenario
      • 8.4.4.3. Regulatory Framework
      • 8.4.4.4. India In Vivo Cell Therapy Market, 2021 - 2033 (USD Million)
    • 8.4.5. Australia
      • 8.4.5.1. Key Country Dynamics
      • 8.4.5.2. Competitive Scenario
      • 8.4.5.3. Regulatory Framework
      • 8.4.5.4. Australia In Vivo Cell Therapy Market, 2021 - 2033 (USD Million)
    • 8.4.6. Thailand
      • 8.4.6.1. Key Country Dynamics
      • 8.4.6.2. Competitive Scenario
      • 8.4.6.3. Regulatory Framework
      • 8.4.6.4. Thailand In Vivo Cell Therapy Market, 2021 - 2033 (USD Million)
    • 8.4.7. South Korea
      • 8.4.7.1. Key Country Dynamics
      • 8.4.7.2. Competitive Scenario
      • 8.4.7.3. Regulatory Framework
      • 8.4.7.4. South Korea In Vivo Cell Therapy Market, 2021 - 2033 (USD Million)
  • 8.5. Latin America
    • 8.5.1. Latin America In Vivo Cell Therapy Market, 2021 - 2033 (USD Million)
    • 8.5.2. Brazil
      • 8.5.2.1. Key Country Dynamics
      • 8.5.2.2. Competitive Scenario
      • 8.5.2.3. Regulatory Framework
      • 8.5.2.4. Brazil In Vivo Cell Therapy Market, 2021 - 2033 (USD Million)
    • 8.5.3. Argentina
      • 8.5.3.1. Key Country Dynamics
      • 8.5.3.2. Competitive Scenario
      • 8.5.3.3. Regulatory Framework
      • 8.5.3.4. Argentina In Vivo Cell Therapy Market, 2021 - 2033 (USD Million)
  • 8.6. MEA
    • 8.6.1. MEA In Vivo Cell Therapy Market, 2021 - 2033 (USD Million)
    • 8.6.2. South Africa
      • 8.6.2.1. Key Country Dynamics
      • 8.6.2.2. Competitive Scenario
      • 8.6.2.3. Regulatory Framework
      • 8.6.2.4. South Africa In Vivo Cell Therapy Market, 2021 - 2033 (USD Million)
    • 8.6.3. Saudi Arabia
      • 8.6.3.1. Key Country Dynamics
      • 8.6.3.2. Competitive Scenario
      • 8.6.3.3. Regulatory Framework
      • 8.6.3.4. Saudi Arabia In Vivo Cell Therapy Market, 2021 - 2033 (USD Million)
    • 8.6.4. UAE
      • 8.6.4.1. Key Country Dynamics
      • 8.6.4.2. Competitive Scenario
      • 8.6.4.3. Regulatory Framework
      • 8.6.4.4. UAE In Vivo Cell Therapy Market, 2021 - 2033 (USD Million)
    • 8.6.5. Kuwait
      • 8.6.5.1. Key Country Dynamics
      • 8.6.5.2. Competitive Scenario
      • 8.6.5.3. Regulatory Framework
      • 8.6.5.4. Kuwait In Vivo Cell Therapy Market, 2021 - 2033 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Company Categorization
  • 9.2. Company Market Share/ Position Analysis, 2025
  • 9.3. Strategy Mapping
  • 9.4. Company Profiles/Listing
    • 9.4.1. Gilead Sciences, Inc.
      • 9.4.1.1. Overview
      • 9.4.1.2. Financial Performance
      • 9.4.1.3. Product Benchmarking
      • 9.4.1.4. Strategic Initiatives
    • 9.4.2. Legend Biotech
      • 9.4.2.1. Overview
      • 9.4.2.2. Financial Performance
      • 9.4.2.3. Product Benchmarking
      • 9.4.2.4. Strategic Initiatives
    • 9.4.3. Eli Lilly and Company
      • 9.4.3.1. Overview
      • 9.4.3.2. Financial Performance
      • 9.4.3.3. Product Benchmarking
      • 9.4.3.4. Strategic Initiatives
    • 9.4.4. CRISPR Therapeutics
      • 9.4.4.1. Overview
      • 9.4.4.2. Financial Performance
      • 9.4.4.3. Product Benchmarking
      • 9.4.4.4. Strategic Initiatives
    • 9.4.5. AbbVie Inc.
      • 9.4.5.1. Overview
      • 9.4.5.2. Financial Performance
      • 9.4.5.3. Product Benchmarking
      • 9.4.5.4. Strategic Initiatives
    • 9.4.6. Umoja Biopharma
      • 9.4.6.1. Overview
      • 9.4.6.2. Financial Performance
      • 9.4.6.3. Product Benchmarking
      • 9.4.6.4. Strategic Initiatives
    • 9.4.7. Ensoma, Inc.
      • 9.4.7.1. Overview
      • 9.4.7.2. Financial Performance
      • 9.4.7.3. Product Benchmarking
      • 9.4.7.4. Strategic Initiatives
    • 9.4.8. Intellia Therapeutics, Inc.
      • 9.4.8.1. Overview
      • 9.4.8.2. Financial Performance
      • 9.4.8.3. Product Benchmarking
      • 9.4.8.4. Strategic Initiatives
    • 9.4.9. Tessera Therapeutics
      • 9.4.9.1. Overview
      • 9.4.9.2. Financial Performance
      • 9.4.9.3. Product Benchmarking
      • 9.4.9.4. Strategic Initiatives
    • 9.4.10. AstraZeneca
      • 9.4.10.1. Overview
      • 9.4.10.2. Financial Performance
      • 9.4.10.3. Product Benchmarking
      • 9.4.10.4. Strategic Initiatives
    • 9.4.11. Johnson & Johnson
      • 9.4.11.1. Overview
      • 9.4.11.2. Financial Performance
      • 9.4.11.3. Product Benchmarking
      • 9.4.11.4. Strategic Initiatives
    • 9.4.12. Valerio Therapeutics
      • 9.4.12.1. Overview
      • 9.4.12.2. Financial Performance
      • 9.4.12.3. Product Benchmarking
      • 9.4.12.4. Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Global in vivo cell therapy market, by therapeutic cell type, 2021 - 2033 (USD million)
  • Table 4 Global in vivo cell therapy market, by therapeutic application, 2021 - 2033 (USD million)
  • Table 5 Global in vivo cell therapy market, by in vivo cell-engineering, 2021 - 2033 (USD million)
  • Table 6 Global in vivo cell therapy market, by delivery modality, 2021 - 2033 (USD million)
  • Table 7 Global in vivo cell therapy market, by region, 2021 - 2033 (USD million)
  • Table 8 North America in vivo cell therapy market, by country, 2021 - 2033 (USD million)
  • Table 9 North America in vivo cell therapy market, by therapeutic cell type, 2021 - 2033 (USD million)
  • Table 10 North America in vivo cell therapy market, by therapeutic application, 2021 - 2033 (USD million)
  • Table 11 North America in vivo cell therapy market, by in vivo cell-engineering, 2021 - 2033 (USD million)
  • Table 12 North America in vivo cell therapy market, by delivery modality, 2021 - 2033 (USD million)
  • Table 13 U.S. in vivo cell therapy market, by therapeutic cell type, 2021 - 2033 (USD million)
  • Table 14 U.S. in vivo cell therapy market, by therapeutic application, 2021 - 2033 (USD million)
  • Table 15 U.S. in vivo cell therapy market, by in vivo cell-engineering, 2021 - 2033 (USD million)
  • Table 16 U.S. in vivo cell therapy market, by delivery modality, 2021 - 2033 (USD million)
  • Table 17 Canada in vivo cell therapy market, by therapeutic cell type, 2021 - 2033 (USD million)
  • Table 18 Canada in vivo cell therapy market, by therapeutic application, 2021 - 2033 (USD million)
  • Table 19 Canada in vivo cell therapy market, by in vivo cell-engineering, 2021 - 2033 (USD million)
  • Table 20 Canada in vivo cell therapy market, by delivery modality, 2021 - 2033 (USD million)
  • Table 21 Mexico in vivo cell therapy market, by therapeutic cell type, 2021 - 2033 (USD million)
  • Table 22 Mexico in vivo cell therapy market, by therapeutic application, 2021 - 2033 (USD million)
  • Table 23 Mexico in vivo cell therapy market, by in vivo cell-engineering, 2021 - 2033 (USD million)
  • Table 24 Mexico in vivo cell therapy market, by delivery modality, 2021 - 2033 (USD million)
  • Table 25 Europe in vivo cell therapy market, by country, 2021 - 2033 (USD million)
  • Table 26 Europe in vivo cell therapy market, by therapeutic cell type, 2021 - 2033 (USD million)
  • Table 27 Europe in vivo cell therapy market, by therapeutic application, 2021 - 2033 (USD million)
  • Table 28 Europe in vivo cell therapy market, by in vivo cell-engineering, 2021 - 2033 (USD million)
  • Table 29 Europe in vivo cell therapy market, by delivery modality, 2021 - 2033 (USD million)
  • Table 30 UK in vivo cell therapy market, by therapeutic cell type, 2021 - 2033 (USD million)
  • Table 31 UK in vivo cell therapy market, by therapeutic application, 2021 - 2033 (USD million)
  • Table 32 UK in vivo cell therapy market, by in vivo cell-engineering, 2021 - 2033 (USD million)
  • Table 33 UK in vivo cell therapy market, by delivery modality, 2021 - 2033 (USD million)
  • Table 34 Germany in vivo cell therapy market, by therapeutic cell type, 2021 - 2033 (USD million)
  • Table 35 Germany in vivo cell therapy market, by therapeutic application, 2021 - 2033 (USD million)
  • Table 36 Germany in vivo cell therapy market, by in vivo cell-engineering, 2021 - 2033 (USD million)
  • Table 37 Germany in vivo cell therapy market, by delivery modality, 2021 - 2033 (USD million)
  • Table 38 France in vivo cell therapy market, by therapeutic cell type, 2021 - 2033 (USD million)
  • Table 39 France in vivo cell therapy market, by therapeutic application, 2021 - 2033 (USD million)
  • Table 40 France in vivo cell therapy market, by in vivo cell-engineering, 2021 - 2033 (USD million)
  • Table 41 France in vivo cell therapy market, by delivery modality, 2021 - 2033 (USD million)
  • Table 42 Italy in vivo cell therapy market, by therapeutic cell type, 2021 - 2033 (USD million)
  • Table 43 Italy in vivo cell therapy market, by therapeutic application, 2021 - 2033 (USD million)
  • Table 44 Italy in vivo cell therapy market, by in vivo cell-engineering, 2021 - 2033 (USD million)
  • Table 45 Italy in vivo cell therapy market, by delivery modality, 2021 - 2033 (USD million)
  • Table 46 Spain in vivo cell therapy market, by therapeutic cell type, 2021 - 2033 (USD million)
  • Table 47 Spain in vivo cell therapy market, by therapeutic application, 2021 - 2033 (USD million)
  • Table 48 Spain in vivo cell therapy market, by in vivo cell-engineering, 2021 - 2033 (USD million)
  • Table 49 Spain in vivo cell therapy market, by delivery modality, 2021 - 2033 (USD million)
  • Table 50 Denmark in vivo cell therapy market, by therapeutic cell type, 2021 - 2033 (USD million)
  • Table 51 Denmark in vivo cell therapy market, by therapeutic application, 2021 - 2033 (USD million)
  • Table 52 Denmark in vivo cell therapy market, by in vivo cell-engineering, 2021 - 2033 (USD million)
  • Table 53 Denmark in vivo cell therapy market, by delivery modality, 2021 - 2033 (USD million)
  • Table 54 Sweden in vivo cell therapy market, by therapeutic cell type, 2021 - 2033 (USD million)
  • Table 55 Sweden in vivo cell therapy market, by therapeutic application, 2021 - 2033 (USD million)
  • Table 56 Sweden in vivo cell therapy market, by in vivo cell-engineering, 2021 - 2033 (USD million)
  • Table 57 Sweden in vivo cell therapy market, by delivery modality, 2021 - 2033 (USD million)
  • Table 58 Norway in vivo cell therapy market, by therapeutic cell type, 2021 - 2033 (USD million)
  • Table 59 Norway in vivo cell therapy market, by therapeutic application, 2021 - 2033 (USD million)
  • Table 60 Norway in vivo cell therapy market, by in vivo cell-engineering, 2021 - 2033 (USD million)
  • Table 61 Norway in vivo cell therapy market, by delivery modality, 2021 - 2033 (USD million)
  • Table 62 Asia Pacific in vivo cell therapy market, by country, 2021 - 2033 (USD million)
  • Table 63 Asia Pacific in vivo cell therapy market, by therapeutic cell type, 2021 - 2033 (USD million)
  • Table 64 Asia Pacific in vivo cell therapy market, by therapeutic application, 2021 - 2033 (USD million)
  • Table 65 Asia Pacific in vivo cell therapy market, by in vivo cell-engineering, 2021 - 2033 (USD million)
  • Table 66 Asia Pacific in vivo cell therapy market, by delivery modality, 2021 - 2033 (USD million)
  • Table 67 Japan in vivo cell therapy market, by therapeutic cell type, 2021 - 2033 (USD million)
  • Table 68 Japan in vivo cell therapy market, by therapeutic application, 2021 - 2033 (USD million)
  • Table 69 Japan in vivo cell therapy market, by in vivo cell-engineering, 2021 - 2033 (USD million)
  • Table 70 Japan in vivo cell therapy market, by delivery modality, 2021 - 2033 (USD million)
  • Table 71 China in vivo cell therapy market, by therapeutic cell type, 2021 - 2033 (USD million)
  • Table 72 China in vivo cell therapy market, by therapeutic application, 2021 - 2033 (USD million)
  • Table 73 China in vivo cell therapy market, by in vivo cell-engineering, 2021 - 2033 (USD million)
  • Table 74 China in vivo cell therapy market, by delivery modality, 2021 - 2033 (USD million)
  • Table 75 India in vivo cell therapy market, by therapeutic cell type, 2021 - 2033 (USD million)
  • Table 76 India in vivo cell therapy market, by therapeutic application, 2021 - 2033 (USD million)
  • Table 77 India in vivo cell therapy market, by in vivo cell-engineering, 2021 - 2033 (USD million)
  • Table 78 India in vivo cell therapy market, by delivery modality, 2021 - 2033 (USD million)
  • Table 79 Australia in vivo cell therapy market, by therapeutic cell type, 2021 - 2033 (USD million)
  • Table 80 Australia in vivo cell therapy market, by therapeutic application, 2021 - 2033 (USD million)
  • Table 81 Australia in vivo cell therapy market, by in vivo cell-engineering, 2021 - 2033 (USD million)
  • Table 82 Australia in vivo cell therapy market, by delivery modality, 2021 - 2033 (USD million)
  • Table 83 Thailand in vivo cell therapy market, by therapeutic cell type, 2021 - 2033 (USD million)
  • Table 84 Thailand in vivo cell therapy market, by therapeutic application, 2021 - 2033 (USD million)
  • Table 85 Thailand in vivo cell therapy market, by in vivo cell-engineering, 2021 - 2033 (USD million)
  • Table 86 Thailand in vivo cell therapy market, by delivery modality, 2021 - 2033 (USD million)
  • Table 87 South Korea in vivo cell therapy market, by therapeutic cell type, 2021 - 2033 (USD million)
  • Table 88 South Korea in vivo cell therapy market, by therapeutic application, 2021 - 2033 (USD million)
  • Table 89 South Korea in vivo cell therapy market, by in vivo cell-engineering, 2021 - 2033 (USD million)
  • Table 90 South Korea in vivo cell therapy market, by delivery modality, 2021 - 2033 (USD million)
  • Table 91 Latin America in vivo cell therapy market, by country, 2021 - 2033 (USD million)
  • Table 92 Latin America in vivo cell therapy market, by therapeutic cell type, 2021 - 2033 (USD million)
  • Table 93 Latin America in vivo cell therapy market, by therapeutic application, 2021 - 2033 (USD million)
  • Table 94 Latin America in vivo cell therapy market, by in vivo cell-engineering, 2021 - 2033 (USD million)
  • Table 95 Latin America in vivo cell therapy market, by delivery modality, 2021 - 2033 (USD million)
  • Table 96 Brazil in vivo cell therapy market, by therapeutic cell type, 2021 - 2033 (USD million)
  • Table 97 Brazil in vivo cell therapy market, by therapeutic application, 2021 - 2033 (USD million)
  • Table 98 Brazil in vivo cell therapy market, by in vivo cell-engineering, 2021 - 2033 (USD million)
  • Table 99 Brazil in vivo cell therapy market, by delivery modality, 2021 - 2033 (USD million)
  • Table 100 Argentina in vivo cell therapy market, by therapeutic cell type, 2021 - 2033 (USD million)
  • Table 101 Argentina in vivo cell therapy market, by therapeutic application, 2021 - 2033 (USD million)
  • Table 102 Argentina in vivo cell therapy market, by in vivo cell-engineering, 2021 - 2033 (USD million)
  • Table 103 Argentina in vivo cell therapy market, by delivery modality, 2021 - 2033 (USD million)
  • Table 104 Middle East & Africa in vivo cell therapy market, by country, 2021 - 2033 (USD million)
  • Table 105 Middle East & Africa in vivo cell therapy market, by therapeutic cell type, 2021 - 2033 (USD million)
  • Table 106 Middle East & Africa in vivo cell therapy market, by therapeutic application, 2021 - 2033 (USD million)
  • Table 107 Middle East & Africa in vivo cell therapy market, by in vivo cell-engineering, 2021 - 2033 (USD million)
  • Table 108 Middle East & Africa in vivo cell therapy market, by delivery modality, 2021 - 2033 (USD million)
  • Table 109 South Africa in vivo cell therapy market, by therapeutic cell type, 2021 - 2033 (USD million)
  • Table 110 South Africa in vivo cell therapy market, by therapeutic application, 2021 - 2033 (USD million)
  • Table 111 South Africa in vivo cell therapy market, by in vivo cell-engineering, 2021 - 2033 (USD million)
  • Table 112 South Africa in vivo cell therapy market, by delivery modality, 2021 - 2033 (USD million)
  • Table 113 Saudi Arabia in vivo cell therapy market, by therapeutic cell type, 2021 - 2033 (USD million)
  • Table 114 Saudi Arabia in vivo cell therapy market, by therapeutic application, 2021 - 2033 (USD million)
  • Table 115 Saudi Arabia in vivo cell therapy market, by in vivo cell-engineering, 2021 - 2033 (USD million)
  • Table 116 Saudi Arabia in vivo cell therapy market, by delivery modality, 2021 - 2033 (USD million)
  • Table 117 UAE in vivo cell therapy market, by therapeutic cell type, 2021 - 2033 (USD million)
  • Table 118 UAE in vivo cell therapy market, by therapeutic application, 2021 - 2033 (USD million)
  • Table 119 UAE in vivo cell therapy market, by in vivo cell-engineering, 2021 - 2033 (USD million)
  • Table 120 UAE in vivo cell therapy market, by delivery modality, 2021 - 2033 (USD million)
  • Table 121 Kuwait in vivo cell therapy market, by therapeutic cell type, 2021 - 2033 (USD million)
  • Table 122 Kuwait in vivo cell therapy market, by therapeutic application, 2021 - 2033 (USD million)
  • Table 123 Kuwait in vivo cell therapy market, by in vivo cell-engineering, 2021 - 2033 (USD million)
  • Table 124 Kuwait in vivo cell therapy market, by delivery modality, 2021 - 2033 (USD million)

List of Figures

  • Fig. 1 In Vivo Cell Therapy market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Market formulation & validation
  • Fig. 7 Market outlook
  • Fig. 8 Segment snapshot
  • Fig. 9 Competitive landscape snapshot
  • Fig. 10 Parent market outlook
  • Fig. 11 In Vivo Cell Therapy market driver analysis
  • Fig. 12 In Vivo Cell Therapy market restraint analysis
  • Fig. 13 In Vivo Cell Therapy market: Porter's five forces analysis
  • Fig. 14 In Vivo Cell Therapy market: PESTLE analysis
  • Fig. 15 In Vivo Cell Therapy market: therapeutic cell type outlook and key takeaways
  • Fig. 16 In Vivo Cell Therapy market: therapeutic cell type market share analysis
  • Fig. 17 T cells market, 2021 - 2033 (USD million)
  • Fig. 18 NK cells market, 2021 - 2033 (USD million)
  • Fig. 19 Myeloid cells market, 2021 - 2033 (USD million)
  • Fig. 20 Other immune cells market, 2021 - 2033 (USD million)
  • Fig. 21 In Vivo Cell Therapy market: therapeutic application outlook and key takeaways
  • Fig. 22 In Vivo Cell Therapy market: therapeutic application market share analysis
  • Fig. 23 Hematological malignancies market, 2021 - 2033 (USD million)
  • Fig. 24 Solid tumors market, 2021 - 2033 (USD million)
  • Fig. 25 Autoimmune diseases market, 2021 - 2033 (USD million)
  • Fig. 26 Infectious diseases market, 2021 - 2033 (USD million)
  • Fig. 27 Other therapeutic applications market, 2021 - 2033 (USD million)
  • Fig. 28 In Vivo Cell Therapy market: in vivo cell-engineering outlook and key takeaways
  • Fig. 29 In Vivo Cell Therapy market: in vivo cell-engineering market share analysis
  • Fig. 30 Receptor engineering market, 2021 - 2033 (USD million)
  • Fig. 31 Gene editing & gene modification market, 2021 - 2033 (USD million)
  • Fig. 32 Transient genetic programming market, 2021 - 2033 (USD million)
  • Fig. 33 Other cell-engineering approaches market, 2021 - 2033 (USD million)
  • Fig. 34 In Vivo Cell Therapy market: delivery modality outlook and key takeaways
  • Fig. 35 In Vivo Cell Therapy market: delivery modality market share analysis
  • Fig. 36 Viral vector-based market, 2021 - 2033 (USD million)
  • Fig. 37 Lipid nanoparticle-based market, 2021 - 2033 (USD million)
  • Fig. 38 Other non-viral delivery systems market, 2021 - 2033 (USD million)
  • Fig. 39 Regional marketplace: Key takeaways
  • Fig. 40 North America in vivo cell therapy market, by country, 2021 - 2033 (USD million)
  • Fig. 41 U.S. in vivo cell therapy market, 2021 - 2033 (USD million)
  • Fig. 42 Canada in vivo cell therapy market, 2021 - 2033 (USD million)
  • Fig. 43 Mexico in vivo cell therapy market, 2021 - 2033 (USD million)
  • Fig. 44 Europe in vivo cell therapy market, by country, 2021 - 2033 (USD million)
  • Fig. 45 UK in vivo cell therapy market, 2021 - 2033 (USD million)
  • Fig. 46 Germany in vivo cell therapy market, 2021 - 2033 (USD million)
  • Fig. 47 France in vivo cell therapy market, 2021 - 2033 (USD million)
  • Fig. 48 Italy in vivo cell therapy market, 2021 - 2033 (USD million)
  • Fig. 49 Spain in vivo cell therapy market, 2021 - 2033 (USD million)
  • Fig. 50 Denmark in vivo cell therapy market, 2021 - 2033 (USD million)
  • Fig. 51 Sweden in vivo cell therapy market, 2021 - 2033 (USD million)
  • Fig. 52 Norway in vivo cell therapy market, 2021 - 2033 (USD million)
  • Fig. 53 Asia Pacific in vivo cell therapy market, by country, 2021 - 2033 (USD million)
  • Fig. 54 Japan in vivo cell therapy market, 2021 - 2033 (USD million)
  • Fig. 55 China in vivo cell therapy market, 2021 - 2033 (USD million)
  • Fig. 56 India in vivo cell therapy market, 2021 - 2033 (USD million)
  • Fig. 57 Australia in vivo cell therapy market, 2021 - 2033 (USD million)
  • Fig. 58 Thailand in vivo cell therapy market, 2021 - 2033 (USD million)
  • Fig. 59 South Korea in vivo cell therapy market, 2021 - 2033 (USD million)
  • Fig. 60 Latin America in vivo cell therapy market, by country, 2021 - 2033 (USD million)
  • Fig. 61 Brazil in vivo cell therapy market, 2021 - 2033 (USD million)
  • Fig. 62 Argentina in vivo cell therapy market, 2021 - 2033 (USD million)
  • Fig. 63 MEA in vivo cell therapy market, by country, 2021 - 2033 (USD million)
  • Fig. 64 South Africa in vivo cell therapy market, 2021 - 2033 (USD million)
  • Fig. 65 Saudi Arabia in vivo cell therapy market, 2021 - 2033 (USD million)
  • Fig. 66 UAE in vivo cell therapy market, 2021 - 2033 (USD million)
  • Fig. 67 Kuwait in vivo cell therapy market, 2021 - 2033 (USD million)